93735-22-9

Basic information

• Product Name: 7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine
• Synonyms: 7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine;7-Methoxy-3,4-dihydro-2H-1,4-benzoxazine;7-Methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine
• CAS NO: 93735-22-9
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.19
• Mol File: 93735-22-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 295.512 °C at 760 mmHg
• Flash Point: 111.892 °C
• Appearance: /
• Density: 1.121 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine(93735-22-9)
• EPA Substance Registry System: 7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine(93735-22-9)

Safety Data

• Hazardous Substances Data: 93735-22-9(Hazardous Substances Data)

Usage

General Description

7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine, also known as 7-methoxy-3,4-dihydro-2H-1,4-benzoxazine, is a chemical compound with the molecular formula C9H11NO2. It is a benzoxazine derivative, which is a heterocyclic compound containing a benzene ring fused to an oxazine ring. 7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine is used in the synthesis of organic molecules and pharmaceuticals, and it has potential applications in drug discovery and materials science. Its specific properties and uses may vary depending on its structural isomers and functional groups. Overall, 7-Methoxy-3,4-dihydro-2H-benzo[1,4]oxazine has important implications in organic chemistry and materials research.

Upstream product

• 6529-94-8 7-methoxy-2H-1,4-benzoxazin-3-one 
• 704-14-3 3-methoxy-6-nitro-phenol 
• 6529-91-5 2-chloro-N-(2-hydroxy-4-methoxyphenyl)acetamide 
• 40925-70-0 2-amino-5-methoxyphenol 

Downstream Products

• 104535-37-7 7-hydroxy-3,4-dihydro-2H-1,4-benzoxazine 
• 258524-52-6 4-benzoyl-7-hydroxy-3,4-dihydro-2H-1,4-benzoxazine 
• 1027218-05-8 (7-oxiranylmethoxy-2,3-dihydro-benzo[1,4]oxazin-4-yl)-phenyl-methanone 
• 1357875-89-8 C₁₉H₁₉NO₃S 
• 1338595-13-3 C₂₅H₂₂N₂O₃ 
• 1357471-52-3 C₂₀H₁₉NO₅S 
• 1338594-92-5 (8-methoxy-4-methylsulfanyl-2,3-dihydro-6H-1-oxa-3a-azaphenalen-5-yl)-phenylmethanone 
• 1338594-96-9 C₁₉H₁₇NO₃ 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula I, pharmaceutical compositions comprising a compound of Formula I, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.